Antioxidant supplements for beta-thalassemia
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests whether two antioxidant supplements, N-acetyl cysteine and alpha lipoic acid, can help people with beta-thalassemia. The supplements may reduce the cell damage caused by the disease, potentially improving their health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a confirmed diagnosis of beta-thalassemia.
- You are willing to receive standard care for thalassemia during the study.
- You do not have diabetes.
- You have no history of heart attack, stroke, or significant heart disease.
- You do not have severe liver or kidney problems.
- You are not pregnant, not obese, and not taking other antioxidant or anti-inflammatory medications.
- You do not have other blood disorders, inflammatory diseases, or conditions related to oxidative stress (like cancer or COPD).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy for beta thalassemia. A modified virus is used to deliver a working gene to your blood stem cells, which may help your body produce normal hemoglobin and reduce the need for blood transfusions.
This study tests a medicine called luspatercept to see if it safely helps children with beta-thalassemia need fewer blood transfusions or keep their hemoglobin levels stable. It is for children aged 6 to 17 who either get regular transfusions or have low hemoglobin and few transfusions.
This gene therapy trial uses a modified virus to deliver a healthy gene into your own stem cells. The goal is to help your body make normal red blood cells so you may need fewer or no transfusions.
This trial tests a new treatment called CS-101 for people with beta-thalassemia who need regular blood transfusions. It aims to see if CS-101 can help reduce transfusion needs.
This trial tests a new drug, 9MW3011, in people with a type of beta-thalassemia that does not require regular blood transfusions. The goal is to see if the drug can safely help manage iron overload and improve hemoglobin levels.
This study tests an experimental gene-editing treatment called CS-101 for people with severe beta-thalassemia who need regular blood transfusions. The goal is to see if it can reduce or eliminate the need for transfusions by helping the body make more healthy red blood cells.
Hear when a new Beta-Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.